Skip to main content

Advertisement

SpringerLink
Log in

Current Management Options for Hereditary Angioedema

  • ALLERGIC DERMATOSIS AND URTICARIA (J RING, SECTION EDITOR)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

The aim of treatment of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (HAE-C1-INH) is either treating acute attacks or preventing attacks by using prophylactic treatment. For treating acute attacks, plasma-derived C1 inhibitor (C1-INH) concentrates, a bradykinin B2 receptor antagonist, and a recombinant human C1-INH are available in Europe. In the United States, a plasma-derived C1-INH concentrate, a bradykinin B2 receptor antagonist, and a plasma kallikrein inhibitor have been approved. Fresh frozen plasma is also available for treating acute attacks. Short-term prophylactic treatment focuses on C1-INH and attenuated androgens. Long-term prophylactic treatments include attenuated androgens such as danazol, stanozolol, and oxandrolone, antifibrinolytics, and a plasma-derived C1-INH concentrate. Plasma-derived C1-INH and a bradykinin B2 receptor antagonist are permitted for self-administration and home therapy. The number of management options has increased considerably within the last few years, thus helping to diminish the burden of HAE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as:•• Of major importance

  1. Gösswein T, Kocot A, Emmert G, et al. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet Genome Res. 2008;121:181–8.

    Article  PubMed  Google Scholar 

  2. Pappalardo E, Caccia S, Suffritti C, et al. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol. 2008;45:3536–44.

    Article  PubMed  CAS  Google Scholar 

  3. Davis 3rd AE. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol. 2008;100:S7–12.

    Article  PubMed  CAS  Google Scholar 

  4. Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356:213–7.

    Article  PubMed  CAS  Google Scholar 

  5. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343:1286–9.

    Article  PubMed  CAS  Google Scholar 

  6. Bork K, Wulff K, Hardt J, et al. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol. 2009;124:129–34.

    Article  PubMed  CAS  Google Scholar 

  7. Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc. 2000;75:349–54.

    Article  PubMed  CAS  Google Scholar 

  8. Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc. 2003;134:1088–94.

    PubMed  Google Scholar 

  9. Brackertz D, Kueppers F. Hereditary angioneurotic oedema. Lancet. 1973;2:680.

    Article  PubMed  CAS  Google Scholar 

  10. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001;161:714–8.

    Article  PubMed  CAS  Google Scholar 

  11. Bork K, Meng G, Staubach P, et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion. 2005;45:1774–84.

    Article  PubMed  CAS  Google Scholar 

  12. Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy. 2008;63:751–7.

    Article  PubMed  CAS  Google Scholar 

  13. •• Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124:801–8. This article reported the results of a randomized, placebo-controlled clinical trial with C1-INH concentrate in hereditary angioedema.

    Article  PubMed  CAS  Google Scholar 

  14. Craig TJ, Wasserman RL, Levy RJ, et al. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol. 2010;30:823–9.

    Article  PubMed  CAS  Google Scholar 

  15. Wasserman RL, Levy RJ, Bewtra AK, et al. Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2011;106:62–8.

    Article  PubMed  CAS  Google Scholar 

  16. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996;334:1630–4.

    Article  PubMed  CAS  Google Scholar 

  17. Farkas H, Jakab L, Temesszentandrasi G. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol. 2007;120:941–7.

    Article  PubMed  CAS  Google Scholar 

  18. www.awmf.org/leitlinien/detail/ll/061-029.html Accessed April 24, 2012

  19. Levi M, Choi G, Picavet C, et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol. 2006;117:904–8.

    Article  PubMed  CAS  Google Scholar 

  20. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001207/human_med_001448.jsp&mid=WC0b01ac058001d124 Product information. EPAR. Accessed April 21, 2012

  21. Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991;102:769–73.

    PubMed  CAS  Google Scholar 

  22. Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov. 2004;3:845–52.

    Article  PubMed  CAS  Google Scholar 

  23. Bork K, Yasothan U, Kirkpatrick P. Icatibant. Nat Rev Drug Discov. 2008;7:801–2.

    Article  CAS  Google Scholar 

  24. Wirth K, Hock FJ, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991;102:774–7.

    PubMed  CAS  Google Scholar 

  25. Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007;119:1497–503.

    Article  PubMed  CAS  Google Scholar 

  26. •• Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363:532–41. This article provides information about the results of the first randomized, controlled clinical study of icatibant in hereditary angioedema.

    Article  PubMed  CAS  Google Scholar 

  27. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000899/human_med_000793.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 . Product information. EPAR. Annex 1. Accessed April 21, 2012

  28. Lumry WR, Li HH, Levy RJ. Randomized placebo-controlled trial of the bradykinin B receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107:529–37.

    Article  PubMed  CAS  Google Scholar 

  29. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM260022.pdf. Accessed April 21, 2012

  30. Aberer W, Toubi E (2011) Safety, tolerability and efficacy of self-administered icatibant for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 107:pp A1-A138, A112, P337

  31. Boccon-Gibod I, Bouillet L. Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol. 2012;168:303–7.

    Article  PubMed  CAS  Google Scholar 

  32. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:523–9.

    Article  PubMed  CAS  Google Scholar 

  33. •• Cicardi M, Levy RJ, McNeil DL. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363:523–31. This article provides information about the outcome of a Phase III study concerning safety and efficacy of ecallantide in hereditary angioedema.

    Article  PubMed  CAS  Google Scholar 

  34. Stolz LE, Sheffer AL. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema. Expert Rev Clin Immunol. 2012;8:25–32.

    Article  PubMed  CAS  Google Scholar 

  35. Beck TR, Baird LG. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema (response). J Allergy Clin Immunol. 2006;117:477.

    Article  Google Scholar 

  36. Caballero T, Lopez-Serrano C. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J Allergy Clin Immunol. 2006;117:476–77. discussion 477.

    Article  PubMed  Google Scholar 

  37. www.fda.gov/downloads/…/ucm170334.pdf, Accessed April 21, 2012

  38. •• Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126(821-827):e814. This article reported Phase III study data on the efficacy and safety of rhC1-INH in treating HAE attacks.

    Google Scholar 

  39. Relan A, Haase G, Hack E, et al. Dose justification for recombinant human C1INH for the treatment of acute angioedema attacks in patients with hereditary angioedema. Allergy. 2010;65:445–6.

    Article  Google Scholar 

  40. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100:153–61.

    Article  PubMed  CAS  Google Scholar 

  41. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med. 1972;287:452–4.

    Article  PubMed  CAS  Google Scholar 

  42. •• Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363:513–22. This article provides information about the study data for the efficacy and safety of a nanofiltered C1-INH concentrate for both acute and long-term prophylactic treatment of hereditary angioedema.

    Article  PubMed  CAS  Google Scholar 

  43. Bork K, Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol. 1989;83:677–82.

    Article  PubMed  CAS  Google Scholar 

  44. Tallroth GA. Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate. Int Arch Allergy Immunol. 2011;154:356–9.

    Article  PubMed  CAS  Google Scholar 

  45. Martinez-Saguer I, Heller C, Fischer D, et al. Prophylactic treatment with pasteurised C1 inhibitor in hereditary angioedema (HAE) - a prospective 32 months follow up. Blood. 1999;94(10):2339. Sup 1, Abstract # 1032.

    Google Scholar 

  46. Bork K, Hardt J. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol. 2011;154:81–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Dermatology, Johannes Gutenberg University, Langenbeckstr. 1, 55131, Mainz, Germany

    Konrad Bork

Authors
  1. Konrad Bork
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konrad Bork.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bork, K. Current Management Options for Hereditary Angioedema. Curr Allergy Asthma Rep 12, 273–280 (2012). https://doi.org/10.1007/s11882-012-0273-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-012-0273-4

Keywords

Search

Navigation